Skip to main content
Fig. 1 | AIDS Research and Therapy

Fig. 1

From: An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

Fig. 1

Schematic of studies and treatment regimens included in the indirect treatment comparison. Data from direct comparisons (solid lines and filled circles) between (i) DTG + 3TC and DTG + TD(A)F/FTC (GEMINI-1 and GEMINI-2) and (ii) BIC/FTC/TAF and DTG + TD(A)F/FTC (GS-US-380–1490) were used for indirect comparison (dashed lines and open circles) between (iii) DTG + 3TC and BIC/FTC/TAF. Data from indirect comparison (iii) and direct comparison between (iv) BIC/FTC/TAF and DTG/ABC/3TC (GS-US-380–1489) were used for indirect comparison between (v) DTG + 3TC and DTG/ABC/3TC. ABC, abacavir; BIC, bictegravir; DTG, dolutegravir; FTC, emtricitabine; QD, once daily; TAF, tenofovir alafenamide; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate. aDTG 50 mg + FTC 200 mg/TDF 300 mg QD or TAF 25 mg QD (DTG + TDF/FTC was assumed to be clinically equivalent to DTG + TAF/FTC). bDTG 50 mg + 3TC 300 mg QD. cBIC 50 mg/FTC 200 mg/TAF 25 mg QD. dDTG 50 mg/ABC 600 mg/3TC 300 mg QD

Back to article page